Predicted coverage based on in vitro neutralizing activity of VRC01.
Abstract
<p>Predicted coverage based on in vitro neutralizing activity of VRC01.</p- Dataset
- Dataset
- Medicine
- Microbiology
- Neuroscience
- Pharmacology
- Immunology
- Cancer
- Mental Health
- Infectious Diseases
- Virology
- Computational Biology
- Chemical Sciences not elsewhere classified
- dose
- peak serum VRC 01 levels
- HVTN
- findings HIV Vaccine Trials Network
- 249 IV infusions
- treatment group 1
- treatment group 3
- Serum VRC 01 levels
- 208 SC injections
- Trial registration Clinical Trials Registration
- mg
- Conclusions VRC 01
- CD 4 binding site
- VRC 01 concentrations
- anti-VRC 01 antibodies
- 8 weeks
- CI
- 2 weeks
- VRC 01 administration regimen
- 6 United States
- SHIV
- treatment group 2
- simian-human immunodeficiency virus
- placebo group 3
- IC
- IV infusion series
- VRC 01
- phase 1 randomized trial Background VRC 01
- NCT
- VRC 01 administration